BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

Core Insights - BridgeBio Pharma, Inc. is set to present ten moderated digital posters at the American Heart Association (AHA) Scientific Sessions 2025, highlighting its focus on genetic diseases [1] Group 1: Research Presentations - The presentations will include findings on Acoramidis and its effects on all-cause mortality in patients with the p.V142I (V122I) variant of ATTR-CM, with a specific session on November 8 at 3:15 pm CT [2] - Acoramidis has been shown to reduce all-cause mortality and first cardiovascular hospitalization in patients with variant transthyretin amyloid cardiomyopathy, with results presented on November 8 at 9:15 am CT [2] - Additional findings indicate that Acoramidis lowers NT-proBNP levels in a larger proportion of study participants compared to placebo, independent of atrial fibrillation status [2] Group 2: Demographic and Geographic Insights - A presentation will address demographic disparities in Tafamidis treatment and clinical outcomes across the United States, scheduled for November 8 at 12:15 pm CT [3] - Geographic disparities in the prevalence of transthyretin amyloid cardiomyopathy among U.S. veterans will also be discussed on November 8 at 3:15 pm CT [3] - Insights from the ATTRibute-CM study will reveal associations between serum transthyretin levels at day 28 and cardiovascular outcomes, presented on November 9 at 3:15 pm CT [3] Group 3: Clinical Outcomes and Safety Information - Acoramidis has shown improvement in clinical outcomes, function, quality of life, and NT-proBNP levels in patients with transthyretin amyloid cardiomyopathy, regardless of atrial fibrillation status at baseline [3] - The drug has been associated with a reduction in the risk of all-cause mortality and cardiovascular-related hospitalization in participants with early-stage heart failure, presented on November 8 at 3:15 pm CT [3] - Important safety information indicates that adverse reactions such as diarrhea and upper abdominal pain were reported, with similar discontinuation rates between Acoramidis and placebo [5]